Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.
Juncusol shows anxiolytic and sedative activities, it shows anxiolytic activity at dosages of 10 mg kg; it can induce caspase-3-mediated cytotoxicity in HT22 cells. Juncusol has anti-microbial activity, it shows significant activity against MRSA strains.